Certara IQ™ Global Roadshow
Certara IQ™ is going on the road. From APAC to Europe to North America, our…
CertaraFebruary 12, 2026
Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis
Anti-PD-1 and anti-PD-L1 antibodies have transformed cancer immunotherapy, yet clinical meta-analyses suggest differences in efficacy…
CertaraFebruary 11, 2026
Pediatric Drug Development: From “Wild West” to Model-Informed Confidence
Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…
CertaraFebruary 11, 2026
QSP in Inflammatory Bowel Disease (IBD): From Biomarkers to Clinical Endpoints, with Virtual Patients
Certara supports IBD drug development with a QSP model that predicts Mayo score and CDAI…
CertaraFebruary 10, 2026
Certara Introduces CRF Creator Module in Pinnacle 21® Enterprise for Faster Clinical Study Start-Up in Drug Development
Discover Pinnacle 21® Enterprise Plus' new CRF Creator module, designed to speed clinical study start-up…
CertaraFebruary 6, 2026
Why Many Global Drugs Never Reach Japan
Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…
CertaraFebruary 5, 2026
Ready for ESG NextGen, or still submitting like it’s 2015?
Learn how to prepare for ESG NextGen with automated, compliant submission workflows. Watch the webinar…
CertaraFebruary 5, 2026
Trial Designs: Non-inferiority vs. Superiority vs. Equivalence
Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…
CertaraFebruary 3, 2026
